Sandoz Group (SDZ) Panoramica del titolo
Sandoz Group AG sviluppa, produce e commercializza farmaci generici e biosimilari in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per SDZ dai nostri controlli di rischio.
SDZ Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Sandoz Group AG
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CHF 73.60 |
| Massimo di 52 settimane | CHF 75.90 |
| Minimo di 52 settimane | CHF 43.86 |
| Beta | 0.49 |
| Variazione di 1 mese | 10.61% |
| Variazione a 3 mesi | 14.21% |
| Variazione di 1 anno | 49.53% |
| Variazione a 3 anni | n/a |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 202.26% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 16
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Analysts have lifted the Sandoz Group price target by CHF 5 to CHF 80, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Sandoz Group Sandoz Group agreed US settlements totaling US$478.5 million related to generic drug pricing investigations, reducing a long running source of legal uncertainty.Aggiornamento narrativa • Aug 02
SDZ: Upgraded GLP-1 Ambitions Will Still Face Earnings And Multiple Pressure
Analysts have trimmed their price target for Sandoz Group to around CHF53 from about CHF54, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that align with the recent upgrade highlighted in Street research. What’s in the News for Sandoz Group Sandoz Group received marketing authorisation in Brazil for Owozy, a semaglutide treatment for type-2 diabetes.Recent updates
Aggiornamento narrativa • Aug 16
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Analysts have lifted the Sandoz Group price target by CHF 5 to CHF 80, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Sandoz Group Sandoz Group agreed US settlements totaling US$478.5 million related to generic drug pricing investigations, reducing a long running source of legal uncertainty.Aggiornamento narrativa • Aug 02
SDZ: Upgraded GLP-1 Ambitions Will Still Face Earnings And Multiple Pressure
Analysts have trimmed their price target for Sandoz Group to around CHF53 from about CHF54, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that align with the recent upgrade highlighted in Street research. What’s in the News for Sandoz Group Sandoz Group received marketing authorisation in Brazil for Owozy, a semaglutide treatment for type-2 diabetes.Aggiornamento narrativa • Jul 10
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Analysts have nudged their price expectations higher for Sandoz Group, with the updated fair value estimate moving from about CHF 47.30 to roughly CHF 54.20, as they adjust assumptions around revenue growth, profit margins and the stock's future P/E in light of recent mixed target changes and an upgrade in Street research. Analyst Commentary Street research on Sandoz Group has been mixed, with some firms lifting their targets and others trimming expectations.
Aggiornamento narrativa • Jun 26
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.Articolo di analisi • Jun 19
Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch
Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...Aggiornamento narrativa • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Aggiornamento narrativa • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Aggiornamento narrativa • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Aggiornamento narrativa • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Aggiornamento narrativa • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Aggiornamento narrativa • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Aggiornamento narrativa • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Aggiornamento narrativa • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Aggiornamento narrativa • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Aggiornamento narrativa • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Aggiornamento narrativa • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Aggiornamento narrativa • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Aggiornamento narrativa • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Aggiornamento narrativa • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Aggiornamento narrativa • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Aggiornamento narrativa • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Aggiornamento narrativa • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.Nuova narrativa • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Rendimenti per gli azionisti
| SDZ | CH Pharmaceuticals | CH Mercato | |
|---|---|---|---|
| 7D | -0.2% | 1.7% | -1.1% |
| 1Y | 49.5% | 32.4% | 14.7% |
Ritorno vs Industria: SDZ ha superato il Swiss Pharmaceuticals che ha restituito 32.6 % nell'ultimo anno.
Rendimento vs Mercato: SDZ ha superato il mercato Swiss che ha restituito 14.6 % nell'ultimo anno.
Volatilità dei prezzi
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 2.0% |
Prezzo delle azioni stabile: SDZ non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swiss.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di SDZ è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1886 | 20,000 | Richard Saynor | www.sandoz.com |
Sandoz Group AG sviluppa, produce e commercializza farmaci generici e biosimilari in tutto il mondo. L'azienda copre aree terapeutiche, tra cui cardiovascolare, sistema nervoso centrale, oncologia, malattie infettive, dolore e respiratorie, diabete, immunologia, endocrinologia, ematologia e oftalmologia. Fornisce inoltre un portafoglio di ingredienti farmaceutici attivi e forme di dosaggio finite.
Sandoz Group AG Riepilogo dei fondamenti
| SDZ statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CHF 31.85b |
| Utili (TTM) | CHF 517.15m |
| Ricavi(TTM) | CHF 9.35b |
61.6x
Rapporto P/E3.4x
Rapporto P/SSDZ è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SDZ Conto economico (TTM) | |
|---|---|
| Ricavi | US$11.68b |
| Costo del fatturato | US$6.08b |
| Profitto lordo | US$5.60b |
| Altre spese | US$4.95b |
| Utili | US$646.00m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 1.49 |
| Margine lordo | 47.94% |
| Margine di profitto netto | 5.53% |
| Rapporto debito/patrimonio netto | 65.0% |
Come si è comportato SDZ nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.1%
Rendimento attuale del dividendo68%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/20 03:40 |
| Prezzo dell'azione a fine giornata | 2026/08/20 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sandoz Group AG è coperta da 37 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |